Our results are consistent with previous studies that described the FLT3-ITD mutation in 25%-35%, FLT3-TKD mutation in 7%-10%, and NPM1 in 50%-60% of CN-AML cases [7,21]. The gene discussed is NPM1; the disease is acute myeloid leukemia.